<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vulvar dermatitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vulvar dermatitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vulvar dermatitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Natasha R Johnson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela L Scheinman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alice J Watson, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vulvar dermatitis is a common, vulvar, inflammatory disorder. One-third to one-half of vulvar complaints are due to this condition [<a href="#rid1">1-4</a>]. Patients with vulvar dermatitis often experience chronic irritation or pruritus, which negatively affects their quality of life.</p><p>This topic will discuss the clinical manifestations, diagnosis, and management of vulvar dermatitis. Other inflammatory vulvar dermatoses, vulvar lesions, and vulvar cancer are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory dermatoses</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5558.html" rel="external">"Vulvar lichen sclerosus: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/94795.html" rel="external">"Acute genital ulceration (Lipschütz ulcer)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis of vulvar lesions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/128406.html" rel="external">"Vulvar lesions: Differential diagnosis of red lesions"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/128409.html" rel="external">"Vulvar lesions: Differential diagnosis of yellow, skin-colored, and edematous lesions"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/128407.html" rel="external">"Vulvar lesions: Differential diagnosis of white lesions"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/128408.html" rel="external">"Vulvar lesions: Differential diagnosis of pigmented (black, brown, blue) lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vulvar cancer</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3237.html" rel="external">"Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H4181907110"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The causes of vulvar dermatitis have been traditionally divided into two groups: endogenous (atopic dermatitis, seborrheic dermatitis) and exogenous (irritant or allergic contact dermatitis). However, these categories are not mutually exclusive, and it is possible for both to exist concomitantly in an individual patient:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis </strong>− Although some experts feel that vulvar involvement with atopic dermatitis is unusual (even when there is severe and widespread atopic dermatitis elsewhere), others believe it is more prevalent than previously acknowledged [<a href="#rid5">5-7</a>]. In women with atopic dermatitis at nongenital sites, the occurrence of erythema in the labial folds, the perianal region, and in the gluteal fold probably represents atopic vulvar dermatitis. However, in such cases, it is important to rule out irritant or allergic contact dermatitis as a complicating factor [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritant and allergic contact dermatitis</strong> – Repeated contact with irritants, such as soaps and other personal hygiene products, wipes, deodorants, sweat, and urine  (<a class="graphic graphic_table graphicRef71478" href="/z/d/graphic/71478.html" rel="external">table 1</a>), is the most common cause of vulvar dermatitis. Although exposure to irritants may have been the initial cause of dermatitis, secondary sensitization to allergens can also occur. Common causes of allergic contact dermatitis include fragrances and preservatives in moisturizers and wipes (eg, methylchloroisothiazolinone [MCI] and methylisothiazolinone [MI]).</p><p></p><p class="bulletIndent1">Active and inert constituents of topical medications are a very common etiology of allergic dermatitis of the vulva in women with persistent vulvar symptoms [<a href="#rid9">9</a>]. Contact allergy to topical corticosteroids is also an important cause of vulvar dermatitis that should not be overlooked [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1">Sensitivity to latex or proteins in seminal plasma are infrequent etiologies [<a href="#rid10">10,12</a>]. (See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/13529.html" rel="external">"Allergic reactions to seminal plasma"</a>.)</p><p></p><p class="bulletIndent1">Type I (immediate hypersensitivity) and type IV (delayed type hypersensitivity) reactions to semen have been reported rarely but should be considered in patients with hives or dermatitis that resolves with condom use or upon abstaining from intercourse [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic contact dermatitis</strong> – A less common but described cause of genital rash is systemic contact dermatitis [<a href="#rid15">15-17</a>]. Patients sensitized to a topical allergen can develop contact dermatitis if exposed to that allergen systemically (eg, by ingestion, parenteral administration, or inhalation). Four main groups of allergens are generally responsible: metals (eg, nickel, cobalt, and chromium); medications (eg, <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a>, an ethylenediamine-derived antihistamine, or oral medications that contain propylene glycol); plant and herbal products, fragrances, and flavorings (eg, citrus, wine, beer, cinnamon, cola, curry, vanilla, or other flavorings); and preservatives (eg, formaldehyde in aspartame). (See  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Vulvar tissue is more permeable than exposed skin due to differences in structure, occlusion, hydration, and susceptibility to friction [<a href="#rid12">12,18</a>]. The vulvar skin is particularly vulnerable to irritants. Compared with other body regions, the stratum corneum overlying the vulva appears to function less efficiently as a barrier, thereby permitting increased susceptibility to irritants [<a href="#rid19">19</a>]. As an example, preservatives such as benzalkonium chloride and maleic acid induce a greater response after application to normal vulvar skin than when applied to the skin of the forearm [<a href="#rid20">20</a>].</p><p>The vulvar skin is also sensitive to allergens. New exposure to an allergen is most likely to induce a reaction, although patients may also react to products that they have used for months or years. A delayed hypersensitivity (type IV) reaction takes from 12 to 72 hours to develop, is usually pruritic, and often lasts for several weeks. In acute cases, an exposure occurring up to two weeks prior to the dermatitis can often be identified. In chronic cases, the dermatitis may have been present for months or years; identifying the offending trigger in these patients can be difficult.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In acute vulvar dermatitis, the skin displays mild to severe erythema of varying extent with some scaling in dry areas  (<a class="graphic graphic_picture graphicRef85722 graphicRef66955" href="/z/d/graphic/85722.html" rel="external">picture 1A-B</a>). Fissures may be present along the labial folds. Excoriations from scratching are common and can be complicated by secondary infection with yeast or bacteria (eg, <em>Staphylococcus aureus</em>, <em>Streptococcus pyogenes</em>, or <em>Escherichia coli</em>). Although crusts and scales are commonly observed with dermatitis elsewhere on the body, these signs are often not present in the moist areas of the vulva.</p><p>In chronic cases, the vulvar mucosa is erythematous and may display papillomatosis, a sign of chronic inflammation  (<a class="graphic graphic_picture graphicRef75027" href="/z/d/graphic/75027.html" rel="external">picture 2</a>). The origin of vulvar papillomatosis is uncertain; the papillae can be normal anatomic variants of the vestibular mucosa or a postinflammatory change [<a href="#rid21">21,22</a>]. Papillomatosis is not a cause of vulvar pain. </p><p>The most common symptom of vulvar dermatitis is pruritus, which can be intense and nocturnal. Other symptoms include pain, burning, stinging, or rawness. Symptoms may be exacerbated by heat, sweat, stress, or menstruation. Self-medication and excessive washing of the vulva by women fearful of a lack of cleanliness often aggravate the dermatitis.</p><p>In response to the epithelial irritation and persistent pruritus, the patient may chronically rub and scratch her skin. Repeated cycles of intense itching and scratching result in the thickening of the vulvar skin and accentuation of the normal skin markings (lichenification), a condition called lichen simplex chronicus  (<a class="graphic graphic_picture graphicRef69453" href="/z/d/graphic/69453.html" rel="external">picture 3</a>) [<a href="#rid4">4,23</a>]. Labial skin folds appear greatly exaggerated, often edematous, and pubic hair can be broken or sparse  (<a class="graphic graphic_picture graphicRef59195 graphicRef81018" href="/z/d/graphic/59195.html" rel="external">picture 4A-B</a>) [<a href="#rid9">9,24</a>]. Other changes include hypopigmentation or hyperpigmentation and hyperkeratosis  (<a class="graphic graphic_picture graphicRef68426" href="/z/d/graphic/68426.html" rel="external">picture 5</a>). Due to local moisture, scale is usually absent, and the skin surface appears soft and whitened. (See  <a class="medical medical_review" href="/z/d/html/128406.html" rel="external">"Vulvar lesions: Differential diagnosis of red lesions", section on 'Lichen simplex chronicus'</a>.)</p><p class="headingAnchor" id="H3261461466"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of vulvar dermatitis is in most cases clinical, based on the clinical presentation, a personal or family history of atopy, or a personal history of vulvar exposure to medications, perfumes, or other chemicals causing persistent irritation [<a href="#rid25">25</a>]. Clinicians should have a high index of suspicion of contact allergy in any chronic vulvar dermatitis, and patients should be referred for patch testing.</p><p>The frequency of clinically relevant patch test results in patients with vulvar complaints is high, ranging from 16 to 54 percent [<a href="#rid7">7-9,11,15,26,27</a>]. A skin biopsy is not routinely performed in women with vulvar dermatitis; however, histopathologic examination may be necessary if the diagnosis is uncertain or there is a suspicion of neoplasia. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">History</span><span class="headingEndMark"> — </span>Women with vulvar complaints should be questioned regarding a personal or family history of atopy (eg, atopic dermatitis, asthma, rhinitis, conjunctivitis) or autoimmune diseases. Chronic pruritus should be ascertained. Specific areas to address in the history include:</p><p class="bulletIndent1"><span class="glyph">●</span>What are the patient's major complaints? Pruritus can vary from mild to intolerable, sometimes interfering with sleep or other activities. When the dermatitis involves mucosal areas, burning, rawness, and stinging are more common than pruritus and the symptoms are often exacerbated during menstruation and with coitus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What are the patient's hygienic practices (eg, daily use of panty liners, feminine products, baby wipes)? Women often erroneously regard their personal practices as safe since they have engaged in them for a long time. Additionally, "clean" or natural products present in pantyliners or used directly on the vulva may contain allergens to which patients can become sensitized [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Has the patient undergone gender-affirming surgery and been treated with medications potentially containing allergens [<a href="#rid30">30</a>]?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient wear occlusive clothing, such as tight Lycra garments, confining undergarments, noncotton underwear, or thongs? These types of garments trap sweat, promote candidiasis, chafe the skin, and facilitate allergen penetration in sensitized individuals. Allergy to textile dyes and textile formaldehyde resins may be an additional cause of vaginal pruritus [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient apply any medications (eg, topical antifungals, corticosteroids, anesthetics) or other agents (eg, lubricants, spermicides, perfumed or deodorant soaps) to the vulva? Women seldom reveal this information unless asked directly. Patients with vulvar dermatitis have often been treated with multiple antifungal agents without success. A report that these creams never helped their symptoms is significant information, indicating that <em>Candida</em> is probably not the source of the complaints.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have fecal or urinary incontinence? Both feces and urine are skin irritants. (See  <a class="medical medical_review" href="/z/d/html/142414.html" rel="external">"Incontinence-associated dermatitis", section on 'Introduction'</a>.) </p><p></p><p>Conscientious analysis of the woman's personal practices is the best way to detect potential irritants and allergens in her environment  (<a class="graphic graphic_table graphicRef71478" href="/z/d/graphic/71478.html" rel="external">table 1</a>) as well as habits unhealthy for the vulvar skin. In a study of 530 women attending a specialty clinic for vulvar diseases, over 60 percent of patients described adverse personal hygiene or self-treatment practices when specifically questioned [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical examination should include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Careful visual inspection of the vulva</strong> – Assess for signs of inflammation (erythema, edema, excoriations, fissures, scaling), changes in vulvar architecture (loss/distal flattening of labia minora, adhesions of clitoral prepuce to glans, narrowing of introitus)  (<a class="graphic graphic_picture graphicRef80900" href="/z/d/graphic/80900.html" rel="external">picture 9B</a>), and signs of atrophy, which indicate long-standing inflammation or inflammatory vulvar dermatosis, such as lichen sclerosus  (<a class="graphic graphic_picture graphicRef98770" href="/z/d/graphic/98770.html" rel="external">picture 6</a>) or inverse psoriasis  (<a class="graphic graphic_picture graphicRef56110" href="/z/d/graphic/56110.html" rel="external">picture 7</a>). (See <a class="local">'Inflammatory vulvar dermatoses'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal examination</strong> – Assess for signs of inflammation (erythema, edema erosions, lesions) or atrophy; perform evaluation of vaginal discharge, including pH, odor, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and potassium hydroxide microscopy, and nucleic acid amplification testing (NAAT) to rule out acute vaginitis or desquamative inflammatory vaginitis. Vaginal discharge is usually unremarkable in women with vulvar dermatitis. If <em>Candida</em> is suspected by examination findings, a vaginal culture and/or NAAT should be obtained even if microscopy is negative. (See  <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete skin examination</strong> – Perform a complete examination of the skin as well as of the mouth, nail beds, flexor and extensor surfaces, and scalp for evidence of nongenital dermatitis (eg, atopic dermatitis, seborrheic dermatitis, psoriasis). Look for scaly scalp plaques or nail pitting that suggest psoriasis. Also look for desquamative gingivitis or buccal Wickham striae suggesting lichen planus.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Patch testing</span><span class="headingEndMark"> — </span>Patch testing is recommended to rule out allergic contact dermatitis and may be helpful to distinguish between atopic dermatitis or irritant dermatitis and allergic contact dermatitis. Patch testing should be performed by a specialist (ie, dermatologist or allergist with access to the appropriate testing panels). In addition to standard series of allergens, the patient's own topical medications, popular remedies, or other suspected products should also be tested [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p>Positive patch tests for relevant substances occur in 25 to 60 percent of women with vulvar pruritus; fragrances, medications, and preservatives are most frequently implicated [<a href="#rid9">9,11,34-38</a>]. In a study including 282 women with vulvar symptoms undergoing patch testing with a European standard series and a gynecologic series, 54 percent reacted to one or more allergens [<a href="#rid38">38</a>]. Nickel was the most commonly found allergen, although the authors felt it was not clinically relevant. In contrast, positive reactions to fragrances, topical antibiotics or anesthetics, and patients' own products were almost always relevant  (<a class="graphic graphic_table graphicRef71193" href="/z/d/graphic/71193.html" rel="external">table 2</a>). In a study evaluating iatrogenic causes of allergic contact dermatitis of the genital and perianal area over an 18-year-period, the active agents most commonly causing contact allergy were local anesthetics and corticosteroids, followed by antibiotics, antivirals, antifungals, antihistamines, antiseptics, and nonsteroidal anti-inflammatory drugs [<a href="#rid39">39</a>]. The vehicles causing iatrogenic contact allergy in these patients included wool alcohol (<a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">lanolin</a>) and the preservatives benzoic acid, cetyl alcohol, and macrogol.</p><p class="headingAnchor" id="H8"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Biopsy is not routinely performed in patients with vulvar dermatitis. However, a biopsy may be necessary if the diagnosis cannot be made on clinical grounds or there is suspicion of neoplasia.</p><p class="headingAnchor" id="H2026208792"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>Histopathologically, acute vulvar dermatitis is characterized by spongiosis (intraepidermal edema) and a dermal infiltrate of lymphocytes with occasional eosinophils [<a href="#rid40">40</a>]. Chronic lesions may show changes of lichen simplex chronicus, consisting of elongation, widening of the rete ridges and irregular thickening of the Malpighian layer of rete ridges (acanthosis), hyperkeratosis, and parakeratosis with a modest mid-dermal inflammatory infiltrate [<a href="#rid41">41</a>]. Periodic acid-Schiff stain for yeasts may be helpful if chronic candidal vulvovaginitis is suspected in patients with negative microscopy and culture of vaginal discharge. </p><p class="headingAnchor" id="H9"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Inflammatory vulvar dermatoses (eg, lichen sclerosus, lichen planus, psoriasis, seborrheic dermatitis), infections (eg, human papillomavirus [HPV], herpes simplex, <em>Candida</em>), neoplasia, and vulvar pain syndromes are all sources of vulvar complaints  (<a class="graphic graphic_table graphicRef63761" href="/z/d/graphic/63761.html" rel="external">table 3</a>). These conditions should be ruled out by laboratory tests and skin biopsy, if necessary. (See  <a class="medical medical_review" href="/z/d/html/5450.html" rel="external">"Vulvar lesions: Diagnostic evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"</a> and  <a class="medical medical_review" href="/z/d/html/5413.html" rel="external">"Vulvar pain of unknown cause (vulvodynia): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Inflammatory vulvar dermatoses</span><span class="headingEndMark"> — </span>Common inflammatory dermatoses involving the vulva include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen sclerosus</strong> – Lichen sclerosus is a chronic, progressive, inflammatory mucocutaneous disease of the vulva that occurs in women of all ages, with a peak incidence in prepubertal girls and perimenopausal or postmenopausal women. Pruritus, irritation, and discomfort are the predominant symptoms, although women can be totally asymptomatic even in the presence of active disease. Lichen sclerosus is characterized by "parchment-like" or "cigarette paper" skin, although thickened, hyperplastic, or lichenified areas are not uncommon  (<a class="graphic graphic_picture graphicRef85726 graphicRef78574" href="/z/d/graphic/85726.html" rel="external">picture 8A-B</a>). Fissures and telangiectasia are common. Untreated disease leads to loss of the normal architecture of the external genitalia and constriction of the vaginal orifice  (<a class="graphic graphic_picture graphicRef59461 graphicRef80900" href="/z/d/graphic/59461.html" rel="external">picture 9A-B</a>). The diagnosis can be confirmed by histologic examination of biopsy specimens if either clinical doubt exists about the diagnosis or if there is concern about possible neoplasia [<a href="#rid42">42</a>]. Patients with lichen sclerosus may also develop lichen simplex chronicus from chronic scratching, and more than one biopsy may be necessary for the correct diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5558.html" rel="external">"Vulvar lichen sclerosus: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus</strong> – Vulvar lichen planus may present with erosive, papulosquamous, or hypertrophic lesions. Erosive lichen planus is the most common type and typically involves the inner aspects of the vulva and vagina  (<a class="graphic graphic_picture graphicRef60224" href="/z/d/graphic/60224.html" rel="external">picture 10</a>). In longstanding disease, loss of the labia minora and narrowing of the introitus may be seen  (<a class="graphic graphic_picture graphicRef96570" href="/z/d/graphic/96570.html" rel="external">picture 11</a>). A skin biopsy for routine histopathologic examination can confirm the diagnosis. Immunofluorescence studies are useful to differentiate erosive lichen planus from autoimmune blistering diseases (eg, mucous membrane pemphigoid and pemphigus). (See  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vulvovaginal-gingival syndrome</strong> – Vulvovaginal-gingival syndrome is a variant of erosive lichen planus that can affect the vagina, vulva, and oral cavity  (<a class="graphic graphic_picture graphicRef86885" href="/z/d/graphic/86885.html" rel="external">picture 12</a>) either concurrently or individually [<a href="#rid43">43</a>]. Vulvar lesions are painful, glassy erosions, while those in the vagina are erythematous and friable. Synechiae can develop in the vagina, which may become obliterated with severe disease. Patients typically have irritation, pain, rawness, and soreness and may have a serosanguinous discharge from vaginal involvement. (See  <a class="medical medical_review" href="/z/d/html/5557.html" rel="external">"Vulvar lichen planus", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psoriasis</strong> – Psoriasis appears as bright red, sharply demarcated lesions that are raised above the surrounding normal skin  (<a class="graphic graphic_picture graphicRef56110" href="/z/d/graphic/56110.html" rel="external">picture 7</a>). Silver scales, commonly observed in psoriasis, may be seen on the mons but are not found elsewhere on the vulva. The presence of typical psoriatic lesions on other body areas suggests the diagnosis. A skin biopsy can be performed for confirmation. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Inverse (intertriginous) psoriasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seborrheic dermatitis</strong> – Seborrheic dermatitis is a chronic inflammatory disorder typically involving areas of the body that are rich in sebaceous glands, such as the scalp, face, axilla, groin, and upper trunk. Involvement of the vulva is uncommon. The lesions are erythematous, poorly defined, and scaling. (See  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Infections</span><span class="headingEndMark"> — </span><em>Candida </em>vulvovaginitis causes pruritus, irritation, burning, and soreness of the vulva. Cutaneous findings of lichen simplex chronicus often accompany <em>Candida</em> infection. <em>Candida</em> is less common in postmenopausal women but can occur in those on estrogen replacement or using potent topical corticosteroids (eg, for treatment of lichen sclerosis). <em>Candida</em> infection should be excluded by nucleic acid amplification testing (NAAT) and/or culture. (See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis"</a>.)</p><p>If there is a malodorous vulvar exudate, bacterial cultures of the vulva should be obtained to aid in the diagnosis of secondary bacterial infection. Bacterial cultures of the vagina are not recommended, as the results are usually nonspecific.</p><p>Testing for herpes simplex virus is recommended when recurrent ulcerations are noted, as these may be a sign of genital herpes. (See  <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3349817206"><span class="h2">Vulvar intraepithelial neoplasia</span><span class="headingEndMark"> — </span>Vulvar intraepithelial neoplasia related to HPV infection, or non-HPV related, may cause irritation and pruritus of the vulva or raised  (<a class="graphic graphic_picture graphicRef72661" href="/z/d/graphic/72661.html" rel="external">picture 13</a>) or macular  (<a class="graphic graphic_picture graphicRef74997" href="/z/d/graphic/74997.html" rel="external">picture 14</a>) lesions. Vulvar biopsy is required for the diagnosis. Appropriate sites for biopsy are identified by physical examination and colposcopy.</p><p>The diagnostic evaluation and management of vulvar intraepithelial neoplasia are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)"</a>.)</p><p class="headingAnchor" id="H1278611895"><span class="h2">Vulvar cancer</span><span class="headingEndMark"> — </span>Most patients with vulvar cancer present with a unifocal vulvar plaque, ulcer, or mass (fleshy, nodular, or warty) on the labia majora  (<a class="graphic graphic_picture graphicRef80593" href="/z/d/graphic/80593.html" rel="external">picture 15</a>), whereas the labia minora, perineum, clitoris, and mons are less frequently involved. Pruritus is the most common complaint, especially if there is an underlying inflammatory vulvar dermatoses (eg, lichen sclerosus or lichen simplex chronicus). Bleeding, discharge, or an enlarged inguinal lymph node may also be present, but patients can be asymptomatic as well. Vulvar biopsy is required for diagnosis. (See  <a class="medical medical_review" href="/z/d/html/3237.html" rel="external">"Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment"</a>.)</p><p class="headingAnchor" id="H3734179277"><span class="h2">Paget disease (extramammary)</span><span class="headingEndMark"> — </span>Vulvar Paget disease typically has an eczematous appearance and may occur anywhere on the vulva. It is well demarcated, with slightly raised edges and a red background  (<a class="graphic graphic_picture graphicRef96562" href="/z/d/graphic/96562.html" rel="external">picture 16</a>). Pruritus is the most common symptom. Diagnosis is based upon characteristic histopathology. Vulvar biopsy should be performed in patients with suspicious lesions, including those with persistent pruritic eczematous lesions that fail to resolve within six weeks of appropriate therapy. Invasive adenocarcinomas may be present within or beneath the surface lesion or at distant noncontiguous sites, and a work-up for underlying malignancy should be considered [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/3237.html" rel="external">"Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Vulvar pain syndromes</span><span class="headingEndMark"> — </span>Vulvar pain may be related to a specific disorder (infectious, inflammatory, neoplastic, or neurologic). Vulvodynia refers to vulvar discomfort of unknown etiology, usually described as burning pain accompanied with allodynia on vestibular/vulvar Q-tip examination. Pruritus is uncommon; nevertheless, persistent pruritus and erythema with a negative yeast culture, nonspecific vulvar biopsy, and failure to respond to standard treatment raises the possibility of vulvodynia. Vulvodynia is a diagnosis of exclusion after specific, relevant disorders have been ruled out. (See  <a class="medical medical_review" href="/z/d/html/5413.html" rel="external">"Vulvar pain of unknown cause (vulvodynia): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2394919343"><span class="h2">Vulvovaginal atrophy</span><span class="headingEndMark"> — </span>Vulvovaginal atrophy is characterized by dryness, inflammation, and thinning of the epithelial lining of the vagina and lower urinary tract due to loss of estrogen. Symptoms include vaginal dryness, burning, pruritus, discharge, bleeding, and dyspareunia. Urinary tract symptoms (eg, frequency, recurrent infection) may also occur. The diagnosis is clinical, based upon the typical finding of pale, dry, thin vaginal epithelium that is smooth and shiny with loss of most rugation. Office analysis reveals basic vaginal pH in the absence of other causes (eg, infection, blood, or semen) and parabasal cells on microscopy. (See  <a class="medical medical_review" href="/z/d/html/5464.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The treatment of vulvar dermatitis requires a multimodal approach involving habit modification, appropriate skin care and hygiene practices  (<a class="graphic graphic_table graphicRef64538" href="/z/d/graphic/64538.html" rel="external">table 4</a>), treatment of coexistent infection, control of pruritus, and topical or systemic medication [<a href="#rid25">25</a>]. "Clean" or natural products are not necessarily allergen free and often contain sensitizers that should be avoided [<a href="#rid46">46-48</a>]. An explanation of the condition, emphasizing the need for long-term treatment with maintenance regimens, and vigilance to prevent and diagnose recurrent yeast infections are important factors for success [<a href="#rid4">4</a>]. Therapy that fails to interrupt the itch-scratch cycle will not lead to consistent, prolonged clinical improvement. For persistent cases, a multidisciplinary approach involving gynecologists, dermatologists, and allergists may be necessary.</p><p>In the absence of data from large, randomized trials, we suggest the regimens discussed below based on our clinical experience and results from small, observational studies.</p><p class="headingAnchor" id="H1629819770"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Behavior modification and adoption of appropriate personal care practices are important components of the management of vulvar dermatitis:</p><p class="bulletIndent1"><span class="glyph">●</span>If the patient has clothing or hygiene habits that facilitate dermatitis, these habits must be modified. Key elements of healthy vulvar hygiene are listed in the table  (<a class="graphic graphic_table graphicRef64538" href="/z/d/graphic/64538.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be reassured that skin issues are not the result of a lack of cleanliness and that excessive washing can worsen dermatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Known or suspected allergens and irritants in the environment should be eliminated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gentle skin care should be encouraged. Soaking in warm water, without additives, for five minutes in the morning and night hydrates the skin and relieves vulvar discomfort and pruritus. If the patient does not have access to a bathtub or a sitz bath placed under a toilet seat, a hand-held shower device can be used for hydration. Moisture is then sealed into the skin with the application of a nonallergenic emollient (eg, petroleum jelly) or a topical corticosteroid ointment ("soak and seal").</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient's personal care practices should be reviewed at each visit to ensure ongoing good practices are being followed. </p><p></p><p class="headingAnchor" id="H14"><span class="h2">Diagnosis and treatment of coexistent infection</span><span class="headingEndMark"> — </span>Diagnosis of coexistent infections is essential. If a vaginal or vulvar exudate is present, a vulvar bacterial culture, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and potassium hydroxide (KOH) preparation, and yeast culture should be obtained. If herpes simplex infection is suspected, a viral culture, direct fluorescent antibody (DFA) test, or polymerase chain reaction (PCR) should be performed (see  <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection"</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidiasis</strong> – Candidiasis may be present in the absence of the usual vaginal symptoms and may be the cause of recurrent vulvar fissures. Candidiasis should be excluded in all patients by yeast culture if the organism is not present on wet mount with 10 percent KOH, which is only 50 percent sensitive. It is important to repeat the search for <em>Candida</em> with wet mount and cultures at each follow-up visit, since a previous negative culture does not rule out <em>Candida</em> infection. (See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1">Candidiasis should be treated with oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, assuming the patient is not allergic to this. Oral therapy is preferred to topical therapy because women with infection superimposed on vulvar dermatitis are at increased risk for worsening dermatitis from the irritant effects of topical drugs [<a href="#rid49">49</a>]. For uncomplicated <em>Candida</em> infection, fluconazole 150 mg is given as a one-time dose. Complicated or recurrent infections may require longer courses of therapy or long-term suppression. Nonalbicans yeast do not usually respond to fluconazole and will require alternative treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/141182.html" rel="external">"Candida vulvovaginitis in adults: Recurrent infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial infection</strong> – Vaginal bacterial cultures are not generally useful because many types of bacteria normally colonize the vagina. Heavy growth of <em>Staphylococcus</em> or <em>Streptococcus</em> should be treated [<a href="#rid50">50</a>]. We use <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> (500 mg orally three times per day) or <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">cefadroxil</a> (500 mg orally twice daily) for five to seven days, if appropriate by sensitivity testing. For women allergic to penicillin, we prescribe <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (250 mg as a single oral dose daily for six days). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genital herpes simplex infection</strong> – If herpes simplex virus is detected, appropriate antiviral therapy can be considered in the individual patient based upon the type of infection (primary or recurrent) and severity of symptoms. (See  <a class="medical medical_review" href="/z/d/html/8346.html" rel="external">"Treatment of genital herpes simplex virus infection"</a>.)</p><p></p><p class="headingAnchor" id="H1717231024"><span class="h2">Control of pruritus</span><span class="headingEndMark"> — </span>Oral sedating antipruritic agents such as <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> (a first-generation H1 antihistamine) or <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">doxepin</a> (a tricyclic antidepressant with antihistamine properties) given in the evening may be helpful to control nighttime itching and scratching. Nonsedating antihistamines are of little benefit for vulvar pruritus. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus"</a>.)</p><p><a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">Doxepin</a> is also available as a cream formulation; however, it is a known contact sensitizer and should not be used on inflamed vulvar skin [<a href="#rid51">51</a>]. Additionally, it produced drowsiness in 25 percent of users due to systemic absorption, which is another limitation to its usefulness [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Patients with mild symptoms</span><span class="headingEndMark"> — </span>Mild vulvar dermatitis usually responds to low- to medium-potency topical corticosteroid ointments (groups 4 to 7  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 5</a>)) such as <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> 1% or 2.5%, <a class="drug drug_general" data-topicid="9331" href="/z/d/drug information/9331.html" rel="external">desonide</a> 0.05%, or <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 0.1%. Topical corticosteroids can be used one or more times daily, for two to four weeks, although a clear benefit has not been demonstrated with more than once daily application [<a href="#rid53">53-55</a>]. Therapy is continued indefinitely at the minimum frequency necessary to control pruritus with a goal of less than 14 days per month.</p><p class="headingAnchor" id="H19"><span class="h2">Patients with moderate to severe symptoms</span><span class="headingEndMark"> — </span>For patients with moderate to severe vulvar dermatitis, a high-potency topical corticosteroid in ointment formulation is generally required (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 5</a>)). We prescribe <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate or augmented <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> dipropionate 0.05% ointment at night daily for 30 days and then reevaluate. </p><p>Ointments are preferred to creams because creams contain more preservatives than ointments. Additionally, some high-potency topical corticosteroid creams contain moderate sensitizers, such as formaldehyde-releasing preservatives or methylisothiazolinone (MI). Potent topical steroids have been used for up to 12 weeks on the vulva without adverse effects [<a href="#rid56">56,57</a>].</p><p>Another acceptable regimen is to give one of these steroids twice daily for two weeks, then daily for two weeks, then on Monday and Wednesday and Friday for two weeks, and then reevaluate. If there is a partial response, we either continue corticosteroids for another two weeks or else switch to intralesional injections or topical calcineurin inhibitors. </p><p class="headingAnchor" id="H3000452120"><span class="h2">Corticosteroid-dependent vulvar dermatitis</span><span class="headingEndMark"> — </span>In some patients, corticosteroid-dependent vulvar dermatitis (ie, dermatitis that relapses rapidly after stopping or tapering topical corticosteroids) can be controlled with the use of the calcineurin inhibitors <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.03% ointment or <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream [<a href="#rid58">58,59</a>]. The ointment or cream is applied sparingly twice daily for 14 to 30 days, followed by maintenance therapy twice per week. Intermittent prolonged treatment may be necessary because the dermatitis in many cases recurs upon discontinuation. Some patients cannot tolerate tacrolimus because of burning or stinging. These side effects may be minimized by applying a film of petroleum jelly before applying the ointment. Calcineurin inhibitors can also be used in conjunction with steroids to allow for a more sparing use of steroids.</p><p class="headingAnchor" id="H20"><span class="h2">Patients with severe refractory disease</span><span class="headingEndMark"> — </span>For patients with localized areas of involvement that do not respond to topical therapies, we suggest intralesional corticosteroids. A total of 0.1 to 2 mL of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide 3.3 to 10 mg/mL is given by injecting small amounts to include the entire lesion or plaque  (<a class="graphic graphic_table graphicRef129499" href="/z/d/graphic/129499.html" rel="external">table 6</a>). If helpful, the injection can be repeated at monthly intervals for up to four times a year. Prior application of a small amount of a topical anesthetic, such as EMLA, facilitates injection. Symptomatic localized areas that do not respond to intralesional corticosteroids should be biopsied to exclude malignancy.</p><p>Patients with severe, persistent symptoms may require systemic immunosuppressive therapy. These patients should be managed in conjunction with appropriate specialists including gynecologists, dermatologists, and allergists.</p><p>Oral or intramuscular (IM) corticosteroids can be used for patients experiencing a severe flare such that they cannot tolerate topical application or for patients who require a short-term bridge to other systemic steroid-sparing therapy [<a href="#rid60">60</a>]. The authors prefer the use of oral corticosteroids, so that any adverse side effects can be minimized by titration of dose, which is not possible after IM administration. Oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is given at a dose of 0.5 to 1 mg/kg per day (maximum daily dose 60 mg) for three to seven days and then tapered by 10 to 20 mg every three to seven days. More gradual tapering of treatment can be required for severe disease, and regimens are often customized based on the clinical picture.</p><p>The short- and long-term side effects of systemic steroid therapy are well documented and include hypertension, hyperglycemia (diabetics may require more frequent blood glucose monitoring), weight gain, sleep or mood disturbance, gastritis, and adrenal suppression. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Other systemic immunosuppressants, including <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, that have shown variable efficacy in the management of inflammatory skin diseases such as atopic dermatitis, psoriasis, lichen sclerosus, and lichen planus should be administered by a clinician experienced in their usage.</p><p class="headingAnchor" id="H4089253077"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113637.html" rel="external">"Society guideline links: Vulvar dermatitis"</a>.)</p><p class="headingAnchor" id="H27015444"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83970.html" rel="external">"Patient education: Vulvar itching (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of vulvar dermatitis</strong> – The causes of vulvar dermatitis have been traditionally divided into endogenous (atopic dermatitis, seborrheic dermatitis) and exogenous (irritant or allergic contact dermatitis). However, these categories are not mutually exclusive, and it is possible for both to exist concomitantly in an individual patient. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Acute vulvar dermatitis presents with mild to severe erythema with some scaling in dry areas, fissures, and excoriations from scratching  (<a class="graphic graphic_picture graphicRef85722 graphicRef66955" href="/z/d/graphic/85722.html" rel="external">picture 1A-B</a>). The most common associated symptom is pruritus, which can be intense and nocturnal. Other symptoms include burning, rawness, or stinging. Chronic dermatitis may display papillomatosis or lichenification  (<a class="graphic graphic_picture graphicRef75027" href="/z/d/graphic/75027.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef69453" href="/z/d/graphic/69453.html" rel="external">picture 3</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of vulvar dermatitis can usually be made clinically, based on characteristic symptoms, a personal or family history of atopy, or a personal history of vulvar exposure to potential irritants and allergens  (<a class="graphic graphic_table graphicRef71478" href="/z/d/graphic/71478.html" rel="external">table 1</a>). Patch testing is helpful to distinguish between atopic dermatitis or irritant dermatitis and allergic contact dermatitis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Infection should be excluded by vulvar cultures for <em>Candida</em>, herpes simplex virus (if ulcers are noted), and potential bacterial pathogens. In uncertain cases and those not responding to standard treatment, a biopsy may be necessary to identify an underlying inflammatory dermatosis or neoplasia. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The treatment of vulvar dermatitis requires a multimodal approach involving behavior modifications, appropriate skin care and hygiene practices  (<a class="graphic graphic_table graphicRef64538" href="/z/d/graphic/64538.html" rel="external">table 4</a>), treatment of coexistent infections, control of pruritus, and topical or systemic medication. An explanation of the condition, emphasizing the need for long-term treatment with maintenance regimens, and vigilance to prevent and diagnose recurrent infections are important factors for success (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures</strong> – Soaking in warm water temporarily relieves vulvar discomfort. Sealing in the moisture with medication prescribed or emollient (eg, plain petroleum jelly) is also a mainstay of therapy. A sedating antihistamine such as <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> given in the evening helps to control nighttime itching and scratching. (See <a class="local">'General measures'</a> above and <a class="local">'Control of pruritus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild dermatitis</strong> – For patients with mild symptoms, we suggest low- to medium-potency topical corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">Hydrocortisone</a> 1% or 2.5%, <a class="drug drug_general" data-topicid="9331" href="/z/d/drug information/9331.html" rel="external">desonide</a> 0.05%, or <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 0.1% ointment is applied daily for two to four weeks. Therapy is continued indefinitely, at the minimum frequency necessary to control pruritus, with a goal of less than 14 days per month. (See <a class="local">'Patients with mild symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe dermatitis</strong> – For patients with moderate to severe symptoms, we suggest high-potency topical corticosteroids, such as <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05% or <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> dipropionate 0.05% (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 5</a>)) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical corticosteroids are applied at bedtime daily for 30 days. Ointments are preferred to creams, as they contain fewer preservatives. (See <a class="local">'Patients with moderate to severe symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe refractory dermatitis</strong> – For patients with localized severe vulvar dermatitis that does not respond to high-potency topical corticosteroids, we suggest intralesional corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A total of 1 to 2 mL of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide 3.3 to 10 mg/mL is given by injecting small amounts to include the entire involved area. Localized disease that does not respond to intralesional corticosteroids should be biopsied to exclude malignancy. Patients with severe, persistent symptoms may require systemic immunosuppressive therapy. (See <a class="local">'Patients with severe refractory disease'</a> above.)</p><p></p><p class="headingAnchor" id="H2359774489"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Elizabeth Gunther Stewart, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ball SB, Wojnarowska F. Vulvar dermatoses: lichen sclerosus, lichen planus, and vulval dermatitis/lichen simplex chronicus. Semin Cutan Med Surg 1998; 17:182.</a></li><li><a class="nounderline abstract_t">Fischer G, Spurrett B, Fischer A. The chronically symptomatic vulva: aetiology and management. Br J Obstet Gynaecol 1995; 102:773.</a></li><li><a class="nounderline abstract_t">Fischer GO. The commonest causes of symptomatic vulvar disease: a dermatologist's perspective. Australas J Dermatol 1996; 37:12.</a></li><li><a class="nounderline abstract_t">Guerrero A, Venkatesan A. Inflammatory Vulvar Dermatoses. Clin Obstet Gynecol 2015; 58:464.</a></li><li class="breakAll">Ridley CM, Neill SM. Non-infective cutaneous conditions of the vulva. In: The Vulva, Ridley CM, Neill SM (Eds), Blackwell Science, 1999.</li><li><a class="nounderline abstract_t">Pincus SH. Vulvar dermatoses and pruritus vulvae. Dermatol Clin 1992; 10:297.</a></li><li><a class="nounderline abstract_t">Crone AM, Stewart EJ, Wojnarowska F, Powell SM. Aetiological factors in vulvar dermatitis. J Eur Acad Dermatol Venereol 2000; 14:181.</a></li><li><a class="nounderline abstract_t">Trivedi MK, Woodruff CM, Kornik R, Botto N. Patch Testing in Vulvar Allergic Contact Dermatitis. Dermatitis 2018; 29:95.</a></li><li><a class="nounderline abstract_t">Marren P, Wojnarowska F, Powell S. Allergic contact dermatitis and vulvar dermatoses. Br J Dermatol 1992; 126:52.</a></li><li><a class="nounderline abstract_t">Nardelli A, Degreef H, Goossens A. Contact allergic reactions of the vulva: a 14-year review. Dermatitis 2004; 15:131.</a></li><li><a class="nounderline abstract_t">Lewis FM, Harrington CI, Gawkrodger DJ. Contact sensitivity in pruritus vulvae: a common and manageable problem. Contact Dermatitis 1994; 31:264.</a></li><li><a class="nounderline abstract_t">Woodruff CM, Trivedi MK, Botto N, Kornik R. Allergic Contact Dermatitis of the Vulva. Dermatitis 2018; 29:233.</a></li><li><a class="nounderline abstract_t">Guillet G, Dagregorio G. Seminal fluid as a missed allergen in vulvar allergic contact dermatitis. Contact Dermatitis 2004; 50:318.</a></li><li><a class="nounderline abstract_t">Caminati M, Giorgis V, Palterer B, et al. Allergy and Sexual Behaviours: an Update. Clin Rev Allergy Immunol 2019; 56:269.</a></li><li><a class="nounderline abstract_t">Vermaat H, Smienk F, Rustemeyer T, et al. Anogenital allergic contact dermatitis, the role of spices and flavour allergy. Contact Dermatitis 2008; 59:233.</a></li><li><a class="nounderline abstract_t">Silvestri DL, Barmettler S. Pruritus ani as a manifestation of systemic contact dermatitis: resolution with dietary nickel restriction. Dermatitis 2011; 22:50.</a></li><li><a class="nounderline abstract_t">Admani S, Maghfour J, Jacob SE. Localized systemic contact dermatitis: The vulva as a clue to identify allergen ingestion. Int J Womens Dermatol 2021; 7:843.</a></li><li><a class="nounderline abstract_t">Farage M, Maibach HI. The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures. Contact Dermatitis 2004; 51:201.</a></li><li><a class="nounderline abstract_t">Elsner P, Wilhelm D, Maibach HI. Multiple parameter assessment of vulvar irritant contact dermatitis. Contact Dermatitis 1990; 23:20.</a></li><li><a class="nounderline abstract_t">Britz MB, Maibach HI. Human cutaneous vulvar reactivity to irritants. Contact Dermatitis 1979; 5:375.</a></li><li><a class="nounderline abstract_t">Bergeron C, Ferenczy A, Richart RM, Guralnick M. Micropapillomatosis labialis appears unrelated to human papillomavirus. Obstet Gynecol 1990; 76:281.</a></li><li><a class="nounderline abstract_t">Prieto MA, Gutiérrez JV, Sambucety PS. Vestibular papillae of the vulva. Int J Dermatol 2004; 43:143.</a></li><li><a class="nounderline abstract_t">Lynch PJ. Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatol Ther 2004; 17:8.</a></li><li><a class="nounderline abstract_t">Marren P, Wojnarowska F. Dermatitis of the vulva. Semin Dermatol 1996; 15:36.</a></li><li><a class="nounderline abstract_t">van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol 2022; 36:952.</a></li><li><a class="nounderline abstract_t">Utaş S, Ferahbaş A, Yildiz S. Patients with vulval pruritus: patch test results. Contact Dermatitis 2008; 58:296.</a></li><li><a class="nounderline abstract_t">Haverhoek E, Reid C, Gordon L, et al. Prospective study of patch testing in patients with vulval pruritus. Australas J Dermatol 2008; 49:80.</a></li><li><a class="nounderline abstract_t">Amat-Samaranch V, López-Sánchez C, Tubau C, et al. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. Contact Dermatitis 2022; 87:96.</a></li><li><a class="nounderline abstract_t">Romita P, Foti C, Gullo G, et al. Genital allergic contact dermatitis in response to contact to thyme in a sanitary pad. Contact Dermatitis 2020; 82:169.</a></li><li><a class="nounderline abstract_t">Schlarbaum JP, Kimyon RS, Liou YL, et al. Genital dermatitis in a transgender patient returning from Thailand: A diagnostic challenge. Travel Med Infect Dis 2019; 27:134.</a></li><li><a class="nounderline abstract_t">Preston A, Riemenschneider K, Guenther M, Cruz PD. Textile-induced vulvar and perianal dermatitis. Contact Dermatitis 2019; 81:66.</a></li><li><a class="nounderline abstract_t">Marin MG, King R, Sfameni S, Dennerstein GJ. Adverse behavioral and sexual factors in chronic vulvar disease. Am J Obstet Gynecol 2000; 183:34.</a></li><li><a class="nounderline abstract_t">Bauer A, Rodiger C, Greif C, et al. Vulvar dermatoses--irritant and allergic contact dermatitis of the vulva. Dermatology 2005; 210:143.</a></li><li><a class="nounderline abstract_t">Goldsmith PC, Rycroft RJ, White IR, et al. Contact sensitivity in women with anogenital dermatoses. Contact Dermatitis 1997; 36:174.</a></li><li><a class="nounderline abstract_t">Virgili A, Bacilieri S, Corazza M. Evaluation of contact sensitization in vulvar lichen simplex chronicus. A proposal for a battery of selected allergens. J Reprod Med 2003; 48:33.</a></li><li><a class="nounderline abstract_t">Margesson LJ. Contact dermatitis of the vulva. Dermatol Ther 2004; 17:20.</a></li><li><a class="nounderline abstract_t">O'Gorman SM, Torgerson RR. Allergic contact dermatitis of the vulva. Dermatitis 2013; 24:64.</a></li><li><a class="nounderline abstract_t">Al-Niaimi F, Felton S, Williams J. Patch testing for vulval symptoms: our experience with 282 patients. Clin Exp Dermatol 2014; 39:439.</a></li><li><a class="nounderline abstract_t">Gilissen L, Schollaert I, Huygens S, Goossens A. Iatrogenic allergic contact dermatitis in the (peri)anal and genital area. Contact Dermatitis 2021; 84:431.</a></li><li><a class="nounderline abstract_t">Hoang MP, Reutter J, Papalas JA, et al. Vulvar inflammatory dermatoses: an update and review. Am J Dermatopathol 2014; 36:689.</a></li><li class="breakAll">www.asccp.org/edu/practice/vulva/squamous.shtml (Accessed on January 10, 2008).</li><li><a class="nounderline abstract_t">Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. J Eur Acad Dermatol Venereol 2015; 29:e1.</a></li><li><a class="nounderline abstract_t">Pelisse M. The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus. Int J Dermatol 1989; 28:381.</a></li><li><a class="nounderline abstract_t">Lopes Filho LL, Lopes IM, Lopes LR, et al. Mammary and extramammary Paget's disease. An Bras Dermatol 2015; 90:225.</a></li><li><a class="nounderline abstract_t">Schmitt AR, Long BJ, Weaver AL, et al. Evidence-Based Screening Recommendations for Occult Cancers in the Setting of Newly Diagnosed Extramammary Paget Disease. Mayo Clin Proc 2018; 93:877.</a></li><li><a class="nounderline abstract_t">Young PA, Gui H, Bae GH. Prevalence of Contact Allergens in Natural Skin Care Products From US Commercial Retailers. JAMA Dermatol 2022; 158:1323.</a></li><li><a class="nounderline abstract_t">Urban K, Giesey R, Delost G. A Guide to Informed Skincare: The Meaning of Clean, Natural, Organic, Vegan, and Cruelty-Free. J Drugs Dermatol 2022; 21:1012.</a></li><li><a class="nounderline abstract_t">Rubin CB, Brod B. Natural Does Not Mean Safe-The Dirt on Clean Beauty Products. JAMA Dermatol 2019; 155:1344.</a></li><li><a class="nounderline abstract_t">Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203.</a></li><li><a class="nounderline abstract_t">Herbst R. Perineal streptococcal dermatitis/disease: recognition and management. Am J Clin Dermatol 2003; 4:555.</a></li><li><a class="nounderline abstract_t">Taylor JS, Praditsuwan P, Handel D, Kuffner G. Allergic contact dermatitis from doxepin cream. One-year patch test clinic experience. Arch Dermatol 1996; 132:515.</a></li><li><a class="nounderline abstract_t">Elmariah SB, Lerner EA. Topical therapies for pruritus. Semin Cutan Med Surg 2011; 30:118.</a></li><li><a class="nounderline abstract_t">Jones SM, Sampson HA. The role of allergens in atopic dermatitis. Clin Rev Allergy 1993; 11:471.</a></li><li><a class="nounderline abstract_t">Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133:592.</a></li><li><a class="nounderline abstract_t">Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005; 152:130.</a></li><li><a class="nounderline abstract_t">Dalziel KL, Wojnarowska F. Long-term control of vulval lichen sclerosus after treatment with a potent topical steroid cream. J Reprod Med 1993; 38:25.</a></li><li><a class="nounderline abstract_t">Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124:461.</a></li><li><a class="nounderline abstract_t">Goldstein AT, Parneix-Spake A, McCormick CL, Burrows LJ. Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: an open-label, preliminary trial. Gynecol Obstet Invest 2007; 64:180.</a></li><li><a class="nounderline abstract_t">Black RJ. Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin Exp Dermatol 2005; 30:91.</a></li><li class="breakAll">American Academy of Dermatology. Atopic dermatitis clinical guideline. https://www.aad.org/practice-tools/quality-care/clinical-guidelines/atopic-dermatitis (Accessed on February 03, 2016).</li></ol></div><div id="topicVersionRevision">Topic 5563 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759675" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Vulvar dermatoses: lichen sclerosus, lichen planus, and vulval dermatitis/lichen simplex chronicus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7547732" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The chronically symptomatic vulva: aetiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8936065" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The commonest causes of symptomatic vulvar disease: a dermatologist's perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26125955" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Inflammatory Vulvar Dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26125955" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Inflammatory Vulvar Dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1606761" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vulvar dermatoses and pruritus vulvae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11032061" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Aetiological factors in vulvar dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29494390" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Patch Testing in Vulvar Allergic Contact Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531610" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Allergic contact dermatitis and vulvar dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15724347" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Contact allergic reactions of the vulva: a 14-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842688" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Contact sensitivity in pruritus vulvae: a common and manageable problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30179968" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Allergic Contact Dermatitis of the Vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15209818" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Seminal fluid as a missed allergen in vulvar allergic contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28653246" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Allergy and Sexual Behaviours: an Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18844699" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anogenital allergic contact dermatitis, the role of spices and flavour allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21291644" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pruritus ani as a manifestation of systemic contact dermatitis: resolution with dietary nickel restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35028397" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Localized systemic contact dermatitis: The vulva as a clue to identify allergen ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15500670" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205447" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Multiple parameter assessment of vulvar irritant contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/527329" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Human cutaneous vulvar reactivity to irritants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2164653" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Micropapillomatosis labialis appears unrelated to human papillomavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125508" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vestibular papillae of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756886" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723822" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dermatitis of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35411963" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2021 European guideline for the management of vulval conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18416761" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Patients with vulval pruritus: patch test results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412806" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prospective study of patch testing in patients with vulval pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35277988" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599970" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genital allergic contact dermatitis in response to contact to thyme in a sanitary pad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30668987" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genital dermatitis in a transgender patient returning from Thailand: A diagnostic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30663079" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Textile-induced vulvar and perianal dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920305" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adverse behavioral and sexual factors in chronic vulvar disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15724097" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vulvar dermatoses--irritant and allergic contact dermatitis of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145281" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Contact sensitivity in women with anogenital dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12611092" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evaluation of contact sensitization in vulvar lichen simplex chronicus. A proposal for a battery of selected allergens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756887" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Contact dermatitis of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23474446" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Allergic contact dermatitis of the vulva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24758600" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Patch testing for vulval symptoms: our experience with 282 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33350482" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Iatrogenic allergic contact dermatitis in the (peri)anal and genital area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25147985" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vulvar inflammatory dermatoses: an update and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25147985" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Vulvar inflammatory dermatoses: an update and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26202852" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2767837" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25830993" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mammary and extramammary Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29804724" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evidence-Based Screening Recommendations for Occult Cancers in the Setting of Newly Diagnosed Extramammary Paget Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36103164" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence of Contact Allergens in Natural Skin Care Products From US Commercial Retailers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36074502" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A Guide to Informed Skincare: The Meaning of Clean, Natural, Organic, Vegan, and Cruelty-Free.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31553406" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Natural Does Not Mean Safe-The Dirt on Clean Beauty Products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500475" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12862498" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Perineal streptococcal dermatitis/disease: recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624147" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Allergic contact dermatitis from doxepin cream. One-year patch test clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767774" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Topical therapies for pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8143262" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The role of allergens in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7577590" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15656813" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441126" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term control of vulval lichen sclerosus after treatment with a potent topical steroid cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039723" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664878" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: an open-label, preliminary trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663517" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
